The Centers for Medicare & Medicaid Services (CMS) is expanding Medicare coverage for genetic testing through the MolDX program administered by Palmetto GBA.
CMS announced two new local coverage determinations (LCDs) to cover diagnostic tests used to evaluate and manage care for patients suspected of having hereditary transthyretin amyloidosis:
The LCDs will take effect Aug. 17 in 23 states.
Source:
https://www.cap.org/advocacy/latest-news-and-practice-data/july-8-2025